Quality of Life in Lyme Disease: What the Netherlands Study Reveals
Quality of life in patients with Lyme disease can be significantly impaired, particularly in those with persistent symptoms following treatment. Findings from the Netherlands PLEASE trial highlight the extent of this burden. :contentReference[oaicite:0]{index=0}
Quality of Life Scores Remain Low
Participants in the PLEASE trial were evaluated using the SF-36 Physical Component Score (PCS), a standard measure of health-related quality of life.
Patients scored between 31 and 32—substantially lower than:
- General population average (~50)
- Diabetes patients (~42)
- Cancer patients (~41)
These findings suggest a significant impact on daily functioning.
Limited Improvement with Treatment
Despite treatment, PCS scores improved only modestly, rising to 34–35.
This level remained well below that of other chronic illnesses and the general population.
Importantly, outcomes were similar whether patients received shorter or longer antibiotic regimens.
Long-Term Outcomes Raise Additional Questions
A companion editorial suggested that patients might take comfort in studies showing long-term recovery.
However, closer examination of these studies shows that a subset of patients continue to experience symptoms for years.
In one long-term study, 11% of patients met criteria for Post-Treatment Lyme Disease Syndrome (PTLDS) 11 to 20 years after treatment.
In another cohort, approximately 14% had PTLDS at 6–12 months, while an additional 38% remained symptomatic. Fewer than half returned to their prior level of health.
Understanding Persistent Symptoms
PTLDS is characterized by ongoing symptoms such as:
- Fatigue
- Musculoskeletal pain
- Cognitive difficulties
- Reduced functional status
These symptoms can have a meaningful impact on quality of life.
Clinical Perspective
The Netherlands trial highlights the need to better understand and address persistent symptoms in Lyme disease.
Potential areas for further evaluation may include:
- Delays in diagnosis and treatment
- Coinfections such as Babesia
- Individual variation in treatment response
Ongoing research is needed to determine which patients may benefit from different or more individualized approaches.
Patients may benefit from understanding persistent symptoms, reviewing testing limitations, and considering coinfections when recovery is incomplete.
References
- Berende A et al. N Engl J Med. 2016.
- Fallon BA et al. Neurology. 2008.
- Krupp LB et al. Neurology. 2003.
- Aucott JN et al. Clin Vaccine Immunol. 2016.
- Weitzner E et al. Diagn Microbiol Infect Dis. 2016.
Dr. Daniel Cameron, MD, MPH
Lyme disease clinician with over 30 years of experience and past president of ILADS.
Symptoms • Testing • Coinfections • Recovery • Pediatric • Prevention
